Equities

Jaguar Health Inc

Jaguar Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.61
  • Today's Change-0.20 / -5.25%
  • Shares traded864.28k
  • 1 Year change-90.95%
  • Beta0.8937
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

  • Revenue in USD (TTM)10.14m
  • Net income in USD-38.32m
  • Incorporated2013
  • Employees49.00
  • Location
    Jaguar Health Inc200 PINE STREET SUITE 400SAN FRANCISCO 94104United StatesUSA
  • Phone+1 (415) 371-8300
  • Fax+1 (302) 655-5049
  • Websitehttps://jaguar.health/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evaxion Biotech A/S - ADR124.00k-14.69m18.36m49.00------148.04-56.83-56.830.0902--------2,530.61---100.11---131.65-----11,846.77-131,560.30------------4.51--65.53--
Synlogic Inc3.21m-73.22m18.38m6.00--1.37--5.73-10.62-10.620.45761.150.0495----534,166.70-113.09-40.57-134.57-43.82-----2,284.68-3,245.93----0.00008--185.685.9913.40---48.05--
Lumos Pharma Inc1.53m-37.13m18.42m33.00--1.06--12.08-4.59-4.590.18862.150.0332--8.0146,212.12-80.89-29.78-90.15-32.32-----2,434.69-2,937.61----0.00--34.67-30.31-9.57------
MEI Pharma Inc66.75m26.16m18.66m46.000.71330.36560.70370.27953.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Vincerx Pharma Inc0.00-38.25m18.69m42.00---------1.79-1.790.00-0.0290.00----0.00-130.68---205.70----------------------36.24------
GlycoMimetics Inc10.00k-37.28m18.95m35.00--0.6552--1,894.61-0.5791-0.57910.00020.44860.0002--0.0581285.71-72.29-43.60-81.84-47.82-----372,767.40-2,243.52----0.00---86.67--20.97---29.82--
KALA BIO Inc0.00-39.55m18.97m43.00--2.85-----15.15-15.150.002.370.00----0.00-63.15-57.83-76.71-69.32--57.06---1,553.61---12.260.8382---100.00--5.85---17.31--
Jaguar Health Inc10.14m-38.32m19.26m49.00--1.50--1.90-78.63-78.639.903.180.18060.23978.12206,938.80-69.22-95.29-122.86-163.5479.0767.28-383.35-522.281.39-2.780.6919---18.3617.1912.97------
Polypid Ltd0.00-24.25m19.43m59.00--2.72-----12.35-12.350.001.490.00----0.00-84.94-76.92-120.03-89.61-----------28.720.5498------39.67---42.34--
AIM ImmunoTech Inc193.00k-31.12m19.49m26.00--4.62--100.97-0.637-0.6370.0040.0960.0072--0.21897,423.08-116.00-45.64-148.40-48.3574.09-231.75-16,123.32-11,695.01----0.3478--43.26-11.26-48.94--35.73--
Nymox Pharmaceutical Corp0.00-4.87m19.62m3.00---------0.0536-0.05360.00-0.02040.00-------255.75-264.40---464.48-------13,001.67---42.44--------47.55------
Lyra Therapeutics Inc1.68m-68.88m19.74m109.00--0.2547--11.75-1.23-1.230.02971.270.0143----19,090.91-58.52-58.01-68.02-68.69-----4,099.82-6,235.31----0.00--14.314.60-13.39--95.14--
Neurobo Pharmaceuticals Inc0.00-16.58m19.84m8.00--1.97-----3.26-3.260.002.050.00----0.00-68.36-95.57-108.01-135.64------------0.00------10.72--75.54--
Correlate Energy Corp7.95m-13.85m20.06m19.00------2.52-0.3747-0.37470.2157-0.1452.76--26.10418,160.50-481.76-315.47----17.9815.42-174.38-201.03---1.07----122.2046.12-78.54------
Minerva Neurosciences Inc0.00-31.60m20.21m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Data as of Jun 07 2024. Currency figures normalised to Jaguar Health Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.